# Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

> **NCT06788912** · PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (estimated)

## Conditions studied

- Lung Neoplasm Malignant

## Interventions

- **BIOLOGICAL:** Pembrolizumab (neoadjuvant)
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Pemetrexed
- **DRUG:** Sacituzumab tirumotecan
- **DRUG:** H1 receptor antagonist
- **DRUG:** H2 receptor antagonist
- **DRUG:** Acetaminophen (or equivalent)
- **DRUG:** Dexamethasone (or equivalent)
- **DRUG:** Carboplatin
- **BIOLOGICAL:** Pembrolizumab (adjuvant)
- **DRUG:** Paclitaxel
- **DRUG:** Steroid mouthwash (dexamethasone or equivalent)

## Key facts

- **NCT ID:** NCT06788912
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-20
- **Primary completion:** 2032-02-06
- **Final completion:** 2032-02-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06788912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06788912, "Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06788912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*